股票 
板块 
用户 
资讯 Swipe Left for English News→
2026年6月17-18日，European Pharma Outsourcing Summit将在德国杜塞尔多夫举行。本次峰会由Generis主办，是制药外包领域的高级别高管会议。会议旨在为制药公司高管提供最新创新成果、战略洞见与行业最佳实践，核心议题涵盖：制药外包趋势、合同制造、供应链优化、制药自动化、合规监管、风险管理、数字化转型等。超过120位制药行业专业人士将齐聚一堂，共同探索提升效率、优化外包与合同制造、确保合规性的实战策略。
今年，面向欧洲及全球制药企业，博腾将亮相本次展会#3展位，全面展示其从临床前研究到药品上市的全生命周期CDMO服务能力，重点聚焦如何帮助客户应对外包过程中的合规挑战、供应链风险及生产灵活性需求。
聚焦峰会：应对外包挑战，优化制药供应链
在本次欧洲制药外包峰会上，博腾将重点展示以下能力如何帮助客户实现降本增效、合规与灵活生产：
全球领先的技术平台
博腾在连续反应、结晶、生物催化、光/电化学等领域拥有领先技术。同时，公司持续投入自动化与数字化，以提升生产透明度和质量可控性，赋能制药供应链优化。
端到端CDMO解决方案
工艺开发（Process Development）
中试生产（Pilot-Scale Production）
商业化GMP制造
博腾提供从临床前到商业化的一体化服务，有效缩短外包管理链条，降低多供应商协调带来的合规与供应风险。
合规与风险管理实践
结合全球监管检查经验（FDA、EMA、PMDA、NMPA、WHO），博腾建立了完善的药品质量体系和风险管理流程。我们将在峰会期间分享如何通过早期介入、质量源于设计（QbD）和技术转移最佳实践，帮助客户实现全生命周期合规。
预约洽谈
欢迎全球制药企业、生物科技公司及外包决策者莅临博腾展位#3，与我们的商务拓展团队进行一对一交流。
预约方式
点击“”访问博腾官网：线下会议
或发送邮件至：business@portonpharma.com，并注明“收件人Angelo Manzo”。
博腾股份成立于2005年，为全球药企、生物科技公司及科研机构等提供从临床前研究到药品上市全生命周期的端到端CDMO服务，涵盖小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物的原料药到制剂全流程。截至2025年末，公司拥有全球员工4300余人，累计服务客户1400余家，成功交付项目超5000个。我们始终坚持以客户为中心，致力于提供创新可靠的全球化CDMO解决方案，让好药更早惠及大众。
On June 17–18, 2026, the European Pharma Outsourcing Summit will take place at the MARITIM HOTEL DüSSELDORF in Düsseldorf, Germany. Organized by Generis, this executive-level pharma conference sets the standard for how the industry connects and exchanges ideas. Tailored for pharmaceutical executives, the summit delivers the latest innovations, strategic insights, and best practices. Key focus areas include pharma outsourcing trends, contract manufacturing, pharmaceutical outsourcing, supply chain optimization, pharma automation, compliance and regulatory affairs, risk management, and digital transformation. More than 120 industry professionals will gather to explore practical strategies for enhancing efficiency, streamlining outsourcing and contract manufacturing, and ensuring compliance in an ever-evolving landscape.
This year, Porton Pharma Solutions will make its debut at the summit at Booth #3. Targeting pharmaceutical companies across Europe and the globe, Porton will present its end-to-end CDMO service capabilities — from preclinical research to commercial.
Porton has successfully passed regulatory inspections from the US FDA, EMA, PMDA, WHO and NMPA, and was honored with the "Global Small Molecule API Award" at the 2025 Outsourced Pharma CDMO Leadership Awards.
What Porton Will Present at Booth #3
Global State-of-the-Art Technology Platforms
Including Flow Chemistry, Crystallization, Biocatalysis, Photo- & Electro-chemistry Technology etc...
End-to-End CDMO Solutions
From process development and pilot-scale production to commercial GMP manufacturing.
Compliance & risk management best practices
Leveraging extensive global regulatory inspection experience to support full-lifecycle quality and compliance.
Schedule a Meeting
Pharmaceutical companies, biotech firms, and outsourcing decision-makers are cordially invited to visit Porton Booth #3 for one-to-one discussions with our business development teams.
What Porton Will Present at Booth #3
Visit the Events page on Porton’s official website.
Email: business@portonpharma.com and please include “Angelo Manzo” in the subject line.
Founded in 2005, Porton Pharma Solutions provides end-to-end CDMO services from pre-clinical to commercial stages. Our capabilities span Small Molecules, TIDES, Biologics and Conjugates (ADCs, AOCs, DACs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products, from drug substance to drug product. As of 2025, Porton has over 4,300 employees globally, served more than 1,400 customers, and delivered over 5,000 projects. We are committed to a customer-centric approach, delivering innovative and reliable global CDMO solutions, enabling earlier access to good medicines.
评论 (0)